Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
Identifieur interne : 003B37 ( Ncbi/Merge ); précédent : 003B36; suivant : 003B38Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.
Auteurs : Helene Bihan [France] ; Winda L. Ng [Australie] ; Dianna J. Magliano [Australie] ; Jonathan E. Shaw [Australie]Source :
- Diabetes research and clinical practice [ 1872-8227 ] ; 2016.
Descripteurs français
- KwdFr :
- Diabète de type 2 (sang), Diabète de type 2 (traitement médicamenteux), Femelle, Glycémie (métabolisme), Humains, Hypoglycémiants (usage thérapeutique), Hémoglobine A glycosylée (métabolisme), Incrétines (usage thérapeutique), Inhibiteurs de la dipeptidyl-peptidase IV (usage thérapeutique), Mâle, Récepteur du peptide-1 similaire au glucagon (agonistes), Résultat thérapeutique.
- MESH :
- agonistes : Récepteur du peptide-1 similaire au glucagon.
- métabolisme : Glycémie, Hémoglobine A glycosylée.
- sang : Diabète de type 2.
- traitement médicamenteux : Diabète de type 2.
- usage thérapeutique : Hypoglycémiants, Incrétines, Inhibiteurs de la dipeptidyl-peptidase IV.
- Femelle, Humains, Mâle, Résultat thérapeutique.
English descriptors
- KwdEn :
- Blood Glucose (metabolism), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (drug therapy), Dipeptidyl-Peptidase IV Inhibitors (therapeutic use), Female, Glucagon-Like Peptide-1 Receptor (agonists), Hemoglobin A, Glycosylated (metabolism), Humans, Hypoglycemic Agents (therapeutic use), Incretins (therapeutic use), Male, Treatment Outcome.
- MESH :
- chemical , agonists : Glucagon-Like Peptide-1 Receptor.
- chemical , metabolism : Blood Glucose, Hemoglobin A, Glycosylated.
- blood : Diabetes Mellitus, Type 2.
- drug therapy : Diabetes Mellitus, Type 2.
- chemical , therapeutic use : Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents, Incretins.
- Female, Humans, Male, Treatment Outcome.
Abstract
To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).
DOI: 10.1016/j.diabres.2016.08.011
PubMed: 27622682
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001611
- to stream PubMed, to step Curation: 001589
- to stream PubMed, to step Checkpoint: 001589
Links to Exploration step
pubmed:27622682Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</title>
<author><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name>
<affiliation wicri:level="4"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27622682</idno>
<idno type="pmid">27622682</idno>
<idno type="doi">10.1016/j.diabres.2016.08.011</idno>
<idno type="wicri:Area/PubMed/Corpus">001611</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001611</idno>
<idno type="wicri:Area/PubMed/Curation">001589</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001589</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001589</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001589</idno>
<idno type="wicri:Area/Ncbi/Merge">003B37</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</title>
<author><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name>
<affiliation wicri:level="4"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetes research and clinical practice</title>
<idno type="eISSN">1872-8227</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blood Glucose (metabolism)</term>
<term>Diabetes Mellitus, Type 2 (blood)</term>
<term>Diabetes Mellitus, Type 2 (drug therapy)</term>
<term>Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)</term>
<term>Female</term>
<term>Glucagon-Like Peptide-1 Receptor (agonists)</term>
<term>Hemoglobin A, Glycosylated (metabolism)</term>
<term>Humans</term>
<term>Hypoglycemic Agents (therapeutic use)</term>
<term>Incretins (therapeutic use)</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diabète de type 2 (sang)</term>
<term>Diabète de type 2 (traitement médicamenteux)</term>
<term>Femelle</term>
<term>Glycémie (métabolisme)</term>
<term>Humains</term>
<term>Hypoglycémiants (usage thérapeutique)</term>
<term>Hémoglobine A glycosylée (métabolisme)</term>
<term>Incrétines (usage thérapeutique)</term>
<term>Inhibiteurs de la dipeptidyl-peptidase IV (usage thérapeutique)</term>
<term>Mâle</term>
<term>Récepteur du peptide-1 similaire au glucagon (agonistes)</term>
<term>Résultat thérapeutique</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Glucagon-Like Peptide-1 Receptor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term>
<term>Hemoglobin A, Glycosylated</term>
</keywords>
<keywords scheme="MESH" qualifier="agonistes" xml:lang="fr"><term>Récepteur du peptide-1 similaire au glucagon</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycémie</term>
<term>Hémoglobine A glycosylée</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dipeptidyl-Peptidase IV Inhibitors</term>
<term>Hypoglycemic Agents</term>
<term>Incretins</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hypoglycémiants</term>
<term>Incrétines</term>
<term>Inhibiteurs de la dipeptidyl-peptidase IV</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27622682</PMID>
<DateCreated><Year>2016</Year>
<Month>09</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>01</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8227</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>121</Volume>
<PubDate><Year>2016</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes research and clinical practice</Title>
<ISOAbbreviation>Diabetes Res. Clin. Pract.</ISOAbbreviation>
</Journal>
<ArticleTitle>Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.</ArticleTitle>
<Pagination><MedlinePgn>27-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0168-8227(16)30434-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabres.2016.08.011</ELocationID>
<Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To identify the determinants of efficacy of glucagon-like peptide-1 receptor agonists (GLP-1A) and dipeptidyl peptidase-4 inhibitors (DPP-4I).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE and EMBASE were searched between 01/01/2011 and 15/08/2014 for randomized controlled trials of 12-52weeks' duration, which reported the change in glycated hemoglobin (HbA1c) from baseline as the primary end point, and reported data about predictors of efficacy of incretins.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4172 studies found, 77 studies reported data on baseline HbA1c, age, sex, ethnicity, body mass index (BMI), and history of diabetes in relation to change in HbA1c. For DPP-4I, 37 out of 47 studies reported a greater decrease in HbA1c among patients with higher baseline HbA1c. Most DPP-4I studies reported no variation in efficacy in regard to demographic characteristics or BMI. Among 17 studies reporting on GLP-1A, baseline higher HbA1c was reported as predictive of a greater response in 7 out of 9 studies; 13 studies reported data about other factors, without consistent findings.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Current evidence suggests that higher baseline HbA1c is associated with a greater efficacy of both DPP-4I and GLP-1A therapies in lowering HbA1c. The roles of other potential predictors are less consistent across studies and require further investigation.</AbstractText>
<CopyrightInformation>Copyright © 2016. Published by Elsevier Ireland Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bihan</LastName>
<ForeName>Helene</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; Department of Endocrinology, Diabetology and Metabolic Disease, Avicenne Hospital, SMBH, Paris 13, Bobigny, France; UMR U557 Inserm/U1125 Inra/CNAM/Université Paris 13, Sorbonne Paris Cité, Bobigny, France. Electronic address: helene.bihan@aphp.fr.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ng</LastName>
<ForeName>Winda L</ForeName>
<Initials>WL</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Magliano</LastName>
<ForeName>Dianna J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shaw</LastName>
<ForeName>Jonathan E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart and Diabetes Institute, Clinical Diabetes and Epidemiology, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, The Alfred Centre, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>08</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Ireland</Country>
<MedlineTA>Diabetes Res Clin Pract</MedlineTA>
<NlmUniqueID>8508335</NlmUniqueID>
<ISSNLinking>0168-8227</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006442">Hemoglobin A, Glycosylated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054795">Incretins</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName>
<QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Hemoglobin A, Glycosylated</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054795" MajorTopicYN="N">Incretins</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Determinant factors</Keyword>
<Keyword MajorTopicYN="N">Diabetes</Keyword>
<Keyword MajorTopicYN="N">Efficacy</Keyword>
<Keyword MajorTopicYN="N">Incretin therapy</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year>
<Month>03</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2016</Year>
<Month>06</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>08</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>1</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>9</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27622682</ArticleId>
<ArticleId IdType="pii">S0168-8227(16)30434-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.diabres.2016.08.011</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Bobigny</li>
<li>Paris</li>
</settlement>
<orgName><li>Université Paris 13</li>
</orgName>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Bihan, Helene" sort="Bihan, Helene" uniqKey="Bihan H" first="Helene" last="Bihan">Helene Bihan</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Ng, Winda L" sort="Ng, Winda L" uniqKey="Ng W" first="Winda L" last="Ng">Winda L. Ng</name>
</noRegion>
<name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name>
<name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003B37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:27622682 |texte= Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27622682" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |